Literature DB >> 7998786

Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands.

J Benedikz1, H Magnússon, G Guthmundsson.   

Abstract

The profile of multiple sclerosis (MS) in Iceland based on a total population study from 1900 to 1990 is reviewed. The first survey in the late 1950s was a retrospective one. Since then, there has been a continuous prospective study that extends over a period of 40 years. The incidence of MS, which was 2.5/100,000 in the 1930s, rose to 3.5 to 4.1/100,000 between 1975 and 1990, but the data from the 1930s must be considered unreliable. There was a similar stepwise increase in prevalence from 30 to approximately 100/100,000 in 1990. It is most likely that the changes in prevalence are the result of improved case ascertainment, the growing number of well-trained neurologists in the country, and the greater awareness of the disease due to the activities of the Icelandic MS Society. No local or regional clusters were identified, but from 1900 to 1980 there was a steady and unexpected increase in the number of cases in rural areas, both by date of clinical onset and date of putative disease acquisition. No evidence was found to support the hypothesis that an epidemic of MS had occurred in Iceland following the arrival of British, Canadian, and American troops during the Second World War. The proposed epidemic in the Faroe Islands was also reexamined, in particular because of the identical ethnic, historical, demographic, and geographical similarities with Iceland. The available data are not supportive of that idea.

Entities:  

Mesh:

Year:  1994        PMID: 7998786     DOI: 10.1002/ana.410360804

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

Review 1.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Type 1 diabetes mellitus and multiple sclerosis: common etiological features.

Authors:  Adam E Handel; Lahiru Handunnetthi; George C Ebers; Sreeram V Ramagopalan
Journal:  Nat Rev Endocrinol       Date:  2009-11-03       Impact factor: 43.330

Review 3.  Development and pilot phase of a European MS register.

Authors:  Peter Flachenecker; Laura Khil; Sverrir Bergmann; Mariusz Kowalewski; Ion Pascu; Francisco Pérez-Miralles; Jaume Sastre-Garriga; Thomas Zwingers
Journal:  J Neurol       Date:  2010-05-05       Impact factor: 4.849

4.  Multiple sclerosis in the Republic of San Marino, Italian peninsula: an incidence and prevalence study from a high-risk area.

Authors:  Marta Caniglia-Tenaglia; Susanna Guttmann; Chiara Monaldini; Dario Manzaroli; Mirco Volpini; Maurizio Stumpo; Elisabetta Groppo; Ilaria Casetta; Vittorio Govoni; Mattia Fonderico; Maura Pugliatti; Enrico Granieri
Journal:  Neurol Sci       Date:  2018-04-18       Impact factor: 3.307

5.  Multiple sclerosis in the province of Ferrara : evidence for an increasing trend.

Authors:  E Granieri; N-T Economou; R De Gennaro; M R Tola; L Caniatti; V Govoni; E Fainardi; I Casetta
Journal:  J Neurol       Date:  2007-11-16       Impact factor: 4.849

6.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

Review 7.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

Review 8.  Surgery and risk for multiple sclerosis: a systematic review and meta-analysis of case-control studies.

Authors:  Carole Lunny; Jennifer A Knopp-Sihota; Shawn N Fraser
Journal:  BMC Neurol       Date:  2013-05-06       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.